Mark Shapiro is the principal investigator for XCELSIOR and BEAT19, two patient-powered real-world data and outcomes registries in cancer and COVID-19, respectively. For two decades he was driven growth and innovation programs in clinical research. Prior to joining xCures, Mr. Shapiro was SVP, Operations at a global CRO, where he was responsible for a team of about 500 drug development professionals in 30 countries, and a portfolio of more than 100 active clinical trials. He was previously a management consultant in the Clinical Development and Medical Affairs consulting practice at Campbell Alliance, now part of Syneos Health Consulting. He also managed a pediatric clinical trials network coordinating center at Duke University focused on clinical, pharmacogenomic, and psychometric research. He has published many peer-reviewed articles on clinical trial design, methods, and the impact of regulatory changes on research and is an author of the PAERS, the Pediatric Adverse Events Rating Scale, which is frequently used in pediatric drug development and several patent applications on the use of AI and Machine Learning in clinical research.